MDxHealth announced that it has signed a commercial agreement with IPS Genomix for the distribution of its SelectMDx® for Prostate Cancer test in the Middle East. With their expert teams covering Lebanon, Egypt, United Arab Emirates, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan, IPS Genomix is ideally positioned to reach the estimated 1 million men across the region with an elevated PSA, who would be potential candidates for SelectMDx.
Under the terms of the agreement, IPS Genomix will handle distribution and reimbursement for SelectMDx within the Middle East, while MDxHealth will perform the SelectMDx testing service in its state-of-the-art ISO certified clinical diagnostic laboratory in Nijmegen, The Netherlands. IPS Genomix will reimburse MDxHealth for all testing services performed.
“We are delighted to announce our collaboration with IPS Genomix for the promotion of SelectMDx across the Middle East,” commented Dr. Jan Groen, CEO of MDxHealth. “IPS Genomix is the ideal partner to bring SelectMDx to physicians, helping to improve both the quality of care and outcomes for patients suspected of harboring aggressive prostate cancer.”
“With more than 25 years of experience in the medical field within the Middle East and Africa, we continuously aim to provide patients with the most effective and appropriate tools for diagnosing and fighting cancer,” stated Ahmed Yacout, Chairman and CEO of IPS Group. “We are excited to partner with MDxHealth and bring together, with our expert teams, this new innovative test to physicians in the region to help optimize prostate cancer diagnosis and management at every level.”
